Literature DB >> 32347509

Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review.

David Rodriguez1,2,3, Carlos Jerjes-Sanchez4,5,6,7, Sugely Fonseca8, Rebeca Garcia-Toto9, Jhon Martinez-Alvarado9, Jathniel Panneflek10, Claudia Ortiz-Ledesma1, Francisco Nevarez1.   

Abstract

Thrombolysis in high-risk pulmonary embolism (PE) patients is recommended worldwide; however, the evidence for thrombolysis during pregnancy and the immediate puerperium remains unclear. We conducted a systematic review from 1950 to 2019 through PubMed, Ovid/Willey, and Cochrane Library to assess the safety and effectiveness of thrombolysis during pregnancy and the immediate puerperium. Additionally, we characterized the clinical presentation, risk stratification, and diagnostic approach. We have communicated our results according to the PRISMA statement. We collected 141 records and, after critical assessment, included 47 case reports of 54 patients, including 43 and 11 patients during pregnancy and puerperium, respectively. During pregnancy, alteplase was the most frequent systemic thrombolytic agent used (67%), but only nine patients received the approved FDA regimen. With catheter-directed thrombolysis, low-dose thrombolytics and fragmentation were the most common regimens. Major bleeding occurred in 18% of cases, but there was no intracranial bleeding. One maternal death occurred secondary to refractory cardiogenic shock. Fetal mortality was 20%. During the immediate puerperium, nine patients received "off-label" first-, second-, and third-generation thrombolytic regimens, and four cases underwent catheter-directed thrombolysis. We observed nine major bleeding events, seven of which were from the uterine location and none of which were intracranial. In conclusion, overall, these data do not suggest prohibitive risk associated with thrombolysis for PE in pregnancy. Management of massive and high-risk submassive PE in pregnancy should be individualized to each patient. In the data presented, no fatal bleeding or intracranial bleeding was observed. Finally, future efforts should systematically collect and report data on high-risk PE in pregnancy and peripartum patients to improve the evidence-base clinical practice.

Entities:  

Keywords:  Peripartum; Postpartum; Pregnancy; Puerperium; Pulmonary embolism; Systematic review; Thrombolytic therapy

Mesh:

Substances:

Year:  2020        PMID: 32347509     DOI: 10.1007/s11239-020-02122-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  3 in total

Review 1.  Acute Coronary Syndrome in Pregnancy and the Post-Partum Period.

Authors:  Anna C O'Kelly; Jonathan Ludmir; Malissa J Wood
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-23

2.  Systemic Thrombolysis for Treatment of Postpartum Saddle Embolism Complicated by Postpartum Hemorrhage: A Case Report and Brief Literature Review.

Authors:  Kathy Mostajeran; Hillary Boswell; Ziad Haidar
Journal:  Case Rep Obstet Gynecol       Date:  2021-06-29

3.  Inter-Specialty Controversies on the Treatment of Cardiovascular Diseases during Pregnancy: A Questionnaire Study.

Authors:  Dominika Dziadosz; Katarzyna Dudzic; Irmina Morawska; Dominika Topolska; Katarzyna Urban; Katarzyna Mizia-Stec; Łukasz J Krzych
Journal:  Medicina (Kaunas)       Date:  2022-01-17       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.